|View printer-friendly version|
|Array BioPharma to Present Phase IA Data From Anti-Cancer Compound at the AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics|
BOULDER, Colo., Nov. 8 /PRNewswire-FirstCall/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that a scientific poster on its anti-cancer compound, ARRY-142886 (AZD6244), will be presented at the AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics in Philadelphia, Pennsylvania.
Poster: "A First in Human Dose-Ranging Study to Assess the
Pharmacokinetics, Pharmacodynamics and Toxicities of the MEK
Inhibitor, ARRY-142886 (AZD6244) in Patients with Advanced
A PDF of each poster will be available for viewing on Array's website at www.arraybiopharma.com on Monday, November 21.
About Array BioPharma:
Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of orally active drugs to address significant unmet medical needs. Our proprietary drug development pipeline is primarily focused on the treatment of cancer and inflammatory disease and includes several small molecule drug candidates that are designed to regulate targets in therapeutically important biologic pathways. In addition, leading pharmaceutical and biotechnology companies access our drug discovery technologies and expertise through collaborations to design, create, optimize and evaluate drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.
SOURCE Array BioPharma Inc.